title: Analysis of stepwise genetic changes in an AIDS-related Burkitt's lymphoma.
abstract: In this study, immunoglobulin variable (Ig V) region genes, c-myc re-arrangement and sequence and p53 status were analyzed in clones derived from a Burkitt's lymphoma cell line (LAM) in which it was previously demonstrated that Epstein-Barr virus (EBV) infection occurred late during lymphomagenesis. Such evidence was based on the finding that 2 groups of cellular clones, characterized by the same c-myc re-arrangement but different EBV-fused termini, were obtained from the LAM cell line. The Ig V gene sequences were identical for the 2 groups of clones with different EBV-fused termini. The Ig variable heavy (V(H)) gene sequence displayed a substantial accumulation of point mutations (but no intra-clonal diversification), whereas the productive Ig V lambda (V(lambda)) gene sequence was virtually unmutated. Studies on the Ig V kappa (V(kappa)) locus suggested a receptor revision event (with a switch from kappa to lambda chain production) prior to EBV infection. Likewise, it was determined that the mutations observed in both p53 alleles and in the re-arranged c-myc gene occurred before EBV infection. Based on these findings, we present a model for the various steps of lymphomagenesis. It is proposed that stimulation by an antigen or a superantigen initially favored the clonal expansion and accumulation of other cytogenetic changes, including those involved in receptor editing. These events occurred prior to or during the germinal center (GC) phase of B-cell maturation. Thereafter, possibly upon exit of the cells from the GC, EBV infection occurred, further promoting lymphomagenesis.
authors.affiliation: Clinical Immunology Division, National Cancer Institute, Genoa, Italy. ffais@hp380.ist.unige.it
authors.forename: F
authors.initials: F
authors.lastname: Fais
authors.forename: G
authors.initials: G
authors.lastname: Fronza
authors.forename: S
authors.initials: S
authors.lastname: Roncella
authors.forename: A
authors.initials: A
authors.lastname: Inga
authors.forename: P
authors.initials: P
authors.lastname: Campomenosi
authors.forename: G
authors.initials: G
authors.lastname: Cutrona
authors.forename: A
authors.initials: A
authors.lastname: Pezzolo
authors.forename: F
authors.initials: F
authors.lastname: Fedeli
authors.forename: A
authors.initials: A
authors.lastname: Abbondandolo
authors.forename: N
authors.initials: N
authors.lastname: Chiorazzi
authors.forename: V
authors.initials: V
authors.lastname: Pistoia
authors.forename: M
authors.initials: M
authors.lastname: Ferrarini
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000235:genetics; D001483:Base Sequence; D002051:Burkitt Lymphoma / Q000209:etiology / Q000235:genetics*; D004273:DNA, Neoplasm / Q000032:analysis; D015322:Gene Rearrangement, B-Lymphocyte / Q000235:genetics; D018858:Germinal Center / Q000502:physiology; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000235:genetics*; D008969:Molecular Sequence Data; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics*; D012689:Sequence Homology, Nucleic Acid; D014178:Translocation, Genetic; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D004273:DNA, Neoplasm; D007135:Immunoglobulin Variable Region; D016271:Proto-Oncogene Proteins c-myc; D016159:Tumor Suppressor Protein p53